Hepatitis C News and Research

Latest Hepatitis C News and Research

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the "Diabetes" Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice.

16 Apr 2010

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.

16 Apr 2010

Kidney expert receives international award

Professor Jonathan Craig from the School of Public Health has been honoured for his contribution to the study of kidney disease. The US-based National Kidney Foundation awarded Professor Craig with its 2010 International Distinguished Medal, recognising outstanding accomplishments in the field of nephrology.

16 Apr 2010

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

Thirty percent of patients surveyed experienced an infection as a result of chemotherapy, 45 percent of which were associated with neutropenia or febrile neutropenia according to findings from a pan-European patient and nurse survey presented today at the 7th Annual European Oncology Nursing Society Spring Convention.

15 Apr 2010

Phase 1 clinical trial results of Achillion Pharmaceuticals' ACH-1625 to be presented at EASL meeting

Achillion Pharmaceuticals, Inc. today presented data from the Company's ongoing Phase 1 clinical trial of ACH-1625 to treat hepatitis C at the European Association for the Study of the Liver's International Liver Congress taking place at the Reed Messe Wien Congress Center in Vienna, Austria from April 14-18, 2010.

15 Apr 2010

AstraZeneca contributes $1M for expansion of Nemours/Alfred I. duPont Hospital for Children

Surrounded by over 100 Nemours Associates, Rich Fante, President, AstraZeneca, U.S., presented Nemours President David J. Bailey, MD, MBA with a ceremonial check for $1 million, announcing AstraZeneca's contribution to the expansion of Nemours/Alfred I. duPont Hospital for Children in Wilmington, Delaware.

15 Apr 2010

Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV

Pharmasset, Inc. announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in patients with hepatitis C virus (HCV) genotype 1 who have not been treated previously.

15 Apr 2010

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 14-day, phase IIa clinical trial evaluating IDX184, a novel liver-targeted nucleotide prodrug of 2'-methyl guanosine monophosphate, in HCV-infected patients.

15 Apr 2010

Real-time elastography method depicts liver hardness: Study

Palpation continues to be of great value in modern medicine, both practiced by doctors and as a technique for self-examination. However, palpation is limited to a few accessible organs, and the interpretation of the information sensed by the fingers is highly subjective.

13 Apr 2010

Research finding suggests HCV interference with hepcidin synthesis

Iron overload, a common feature of chronic liver disorders, has been linked with oxidative DNA damage, insulin resistance and liver steatosis, and with triggering of hepatic stellate cells thus inducing liver fibrosis.

13 Apr 2010

Drug boosting production of immune system protein worsens TB

An experimental drug that boosts production of the immune system protein interferon worsens tuberculosis (TB) in mice, according to scientists from the National Institutes of Health. The drug acts indirectly by drawing certain immune cells, in which Mycobacterium tuberculosis (M.tb) bacteria thrive, to the lungs. The findings may have potential implications for the care of people infected with TB, the authors note. The research is reported in the May 3 issue of Journal of Clinical Investigation, now available online.

13 Apr 2010

Checklist to stay healthy and active during summer season

There are millions of vacation destinations to visit this summer and thousands of sights to see, but there is one surefire way to ruin your trip -- getting sick. Although you may not be thinking about viruses and bacterial infections when you plan your trip, there are a few nasty bugs you should be aware of as you pack your bags.

13 Apr 2010

Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles

Inhibitex, Inc. today announced that the independent Data Safety Monitoring Board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with 30-day follow-up data on the first half of the patients that the Company plans to enroll in the trial.

12 Apr 2010

Study shows promising basis for development of effective liver-cancer screening test

Liver cancer is the fifth most common cancer in the world and one of the deadliest cancers since it is rarely diagnosed until late in its development.

12 Apr 2010

WHO Director-General turns attention to conditions in slums to mark World Health Day

WHO Director-General Margaret Chan said addressing living conditions in the world's slums is important to improving urban health - the focus of World Health Day on Wednesday, Agence France-Presse reports.

9 Apr 2010

Inovio Biomedical receives $2.8M grant to develop DNA vaccine for HCV

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company and its collaborators from Drexel University, Cheyney University, and the University of Pennsylvania have received a $2.8 million grant to develop a DNA vaccine to treat hepatitis C virus.

9 Apr 2010

IFN therapy for chronic hepatitis C must be individualized and optimized for efficacy

The efficacy of interferon (IFN) therapy depends on the hepatitis C virus (HCV) genotype, pretreatment viral load and early viral kinetics. Thus, IFN therapy must be individualized and optimized according to the virological and clinical status of each patient.

9 Apr 2010

Combination telaprevir treatment beneficial for retreatment of hepatitis C

A study co-authored by a Saint Louis University researcher found telaprevir, a protease inhibitor, combined with standard hepatitis C treatment, cures a significantly higher number of difficult-to-treat patients than standard treatment alone. The findings were published in the April issue of the New England Journal of Medicine.

9 Apr 2010

12 infected with Hepatitis C by a doctor at clinic in Victoria

Hepatitis C is a vial infection that is spread much like HIV with shared needles, blood or body fluids. The Victorian Police has been brought in to investigate a cluster of 12 hepatitis C positive cases who attended a late-term abortion clinic in Melbourne.

9 Apr 2010

Ribavirin Biopartners 200mg film-coated tablets granted EU marketing approval

Biopartners GmbH has announced that it has received EU marketing authorization from the European Commission for Ribavirin Biopartners 200mg film-coated tablets. The product is intended for the treatment of chronic hepatitis C infection as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b.

9 Apr 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

Kidney expert receives international award

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

Phase 1 clinical trial results of Achillion Pharmaceuticals' ACH-1625 to be presented at EASL meeting

AstraZeneca contributes $1M for expansion of Nemours/Alfred I. duPont Hospital for Children

Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Real-time elastography method depicts liver hardness: Study

Research finding suggests HCV interference with hepcidin synthesis

Drug boosting production of immune system protein worsens TB

Checklist to stay healthy and active during summer season

Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles

Study shows promising basis for development of effective liver-cancer screening test

WHO Director-General turns attention to conditions in slums to mark World Health Day

Inovio Biomedical receives $2.8M grant to develop DNA vaccine for HCV

IFN therapy for chronic hepatitis C must be individualized and optimized for efficacy

Combination telaprevir treatment beneficial for retreatment of hepatitis C

12 infected with Hepatitis C by a doctor at clinic in Victoria

Ribavirin Biopartners 200mg film-coated tablets granted EU marketing approval

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in